Additional sites in Russia and Ukraine in Phase III ovarian cancer trial opened

21 June 2010

Due to the slow recruitment in non- OCT countries, 6 new sites in Russia and 3 sites in Ukraine were opened in Phase III ovarian cancer trial in addition to 47 sites recruiting.

OCT Vision

“OCT vision is to be recognized by pharmaceutical and biotech companies as a leading provider of clinical trials in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania, Estonia, Poland and Czech Republic. OCT is able to support any requirements that clients may have in the region, ranging from one-off advice to full-study implementation and execution. We are determined and decisive in expanding our activity at this rapidly growing market”— Dmitry Sharov, General Manager of OCT.